16:34 EDT Travere Therapeutics trading halted, news pending
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Evercore says Filspari inclusion in new guidelines should give Travere boost
- Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
- Travere Therapeutics price target raised to $20 from $19 at JPMorgan
- Travere Therapeutics to Present at Upcoming Investor Conferences
- Travere Therapeutics price target raised to $20 from $19 at H.C. Wainwright